Experts Discuss Clinical Application of TRK Inhibitors and Tumor Agnostic NTRK Fusion Testing
  • CME

Watch this on-demand Webcast from our live symposium to review the latest clinical data and expert perspectives on targeting TRK in solid tumors, available and emerging TRK inhibitors, and implementing NTRK fusion testing in practice.
Todd M. Bauer, MD
Marcia S. Brose, MD, PhD
George D. Demetri, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: July 15, 2019 Expiration: July 14, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice once approved
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Todd M. Bauer, MD

Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, Armo, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech, GlaxoSmithKline, Immunocore, ImmunoGen, Incyte, Ignyta, Jacobio, Janssen, Leap, Lilly, Loxo, Karyopharm, Kolltan, MabVax, MedImmune, Medpacto, Merck, Mirati, Merrimack, Millennium, Moderna, Novartis, Onyx, Peleton, Pfizer, Phosplatin, Principa, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; has received consulting fees paid to his institution from Ignyta, Leap, Loxo, and Moderna; has received consulting fees from Bayer, Guardan, Loxo, and Pfizer; and has served on the speaker bureau for Bayer.
Marcia S. Brose, MD, PhD

Assistant Professor
Abramson Cancer Center
Department of Otorhinolaryngology: Head & Neck Surgery
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Philadelphia, Pennsylvania

Marcia S. Brose, MD, PhD, has disclosed that she has received consulting fees from Bayer, Blueprint Medicines, and Loxo Oncology and funds for research support paid to her institution from AstraZeneca, Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, Loxo Oncology, and Novartis.
George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees and funds for research support from Bayer, Ignyta, Loxo Oncology, and Roche; has received consulting fees from AbbVie, Adaptimmune, Daiichi-Sankyo, EMD Serono, Epizyme, GlaxoSmithKline, ICON, Janssen, Lilly, Mirati, Novartis, Pfizer, PharmaMar, Polaris, Sanofi, and ZioPharm; has served as a consultant/scientific advisory board member with minor equity holding for Bessor, Caris Life Sciences, Champions Biotechnology, Erasca, and G1 Therapeutics; and has served as an independent member of the board of directors and scientific advisory board consultant with minor equity holding for Blueprint Medicines and Merrimack.


Kristen Rosenthal, PhD

Senior Scientific Director

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other allied healthcare professionals involved in the treatment of cancer.


The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to plan optimal therapy for their patients with cancer.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 15, 2019, through July 14, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

Downloadable slideset reviewing the latest data informing optimal use of immune checkpoint inhibition for the treatment of pretreated SCLC, from Clinical Care Options (CCO)

Anna F. Farago, MD, PhD Taofeek K. Owonikoko, MD, PhD Released: July 9, 2020

In this slideset from Clinical Care Options, John L. Marshall, MD provides insights on the latest data on the use of MSI/MMR testing and immunotherapy for patients with GI cancers.

John L. Marshall, MD Released: July 9, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD outlines the current approach for the use of IO biomarkers and immunotherapy approaches for lung cancer.

Jamie E. Chaft, MD Released: July 9, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Bayer Healthcare Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?